Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Treasury Shares (2017 - 2025)

Sutro Biopharma's Treasury Shares history spans 9 years, with the latest figure at $5.2 million for Q3 2025.

  • For Q3 2025, Treasury Shares fell 13.04% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, down 13.04%, while the annual FY2024 figure was $6.0 million, 13.54% up from the prior year.
  • Treasury Shares for Q3 2025 was $5.2 million at Sutro Biopharma, down from $6.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $6.2 million in Q2 2025 and bottomed at $1.9 million in Q1 2021.
  • The 5-year median for Treasury Shares is $5.2 million (2023), against an average of $4.4 million.
  • The largest annual shift saw Treasury Shares soared 260.73% in 2021 before it crashed 37.05% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $2.4 million in 2021, then surged by 64.67% to $4.0 million in 2022, then soared by 32.5% to $5.2 million in 2023, then increased by 13.54% to $6.0 million in 2024, then fell by 12.05% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Treasury Shares are $5.2 million (Q3 2025), $6.2 million (Q2 2025), and $3.9 million (Q1 2025).